NTLA CIK: 1652130

Intellia Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
billions USD
FY21:
0.77
FY22:
1.22
FY23:
1.00
FY24:
0.64
FY25:
0.53
(positive)
Change from FY21 to FY25
billions USD
FY21:
0.53
FY22:
0.30
FY23:
0.30
FY24:
0.55
FY25:
0.31
Total assets
Change from FY21 to FY25
billions USD
FY21:
1.29
FY22:
1.52
FY23:
1.30
FY24:
1.19
FY25:
0.84

Liabilities & Equity

(negative)
Change from FY21 to FY25
billions USD
FY21:
0.13
FY22:
0.13
FY23:
0.12
FY24:
0.11
FY25:
0.10
(negative)
Change from FY21 to FY25
billions USD
FY21:
0.13
FY22:
0.16
FY23:
0.14
FY24:
0.21
FY25:
0.07
(positive)
Change from FY21 to FY25
billions USD
FY21:
1.04
FY22:
1.24
FY23:
1.05
FY24:
0.87
FY25:
0.67
Total liabilities & equity
Change from FY21 to FY25
billions USD
FY21:
1.29
FY22:
1.52
FY23:
1.30
FY24:
1.19
FY25:
0.84

All amounts in billions USD Data sources:SEC EDGARTwelve Data